Verona Pharma PLC American Depositary Share (VRNA) closed the last trading session at $90.48, gaining 6.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $114 indicates a 26% upside potential.The average comprises 10 short-term price targets ranging from a low of $90.00 to a high of $160.00, with a standard deviation of $23.98. While the lowest estimate indicates a decline of 0.5% ...

Shares of International Seaways (INSW) have gained 6.1% over the past four weeks to close the last trading session at $38.5, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $58.4 indicates a potential upside of 51.7%.The mean estimate comprises five short-term price targets with a standard deviation of $9.94. While the lowest estimate of $48.00 indicates a 24.7% increase from th ...

Shares of Ardmore Shipping (ASC) have gained 6.4% over the past four weeks to close the last trading session at $10.08, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.17 indicates a potential upside of 30.7%.The average comprises three short-term price targets ranging from a low of $12.50 to a high of $14.00, with a standard deviation of $0.76. While the lowest estimate ind ...

Shares of Apogee Therapeutics Inc. (APGE) have gained 9.9% over the past four weeks to close the last trading session at $40.98, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $93.88 indicates a potential upside of 129.1%.The average comprises eight short-term price targets ranging from a low of $78 to a high of $116, with a standard deviation of $11.05. While the lowest estima ...

LifeStance Health Group (LFST) closed the last trading session at $5.95, gaining 8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.63 indicates a 45% upside potential.The average comprises eight short-term price targets ranging from a low of $7 to a high of $10, with a standard deviation of $1.03. While the lowest estimate indicates an increase of 17.7% from the current price l ...

Shares of Synaptics (SYNA) have gained 7.3% over the past four weeks to close the last trading session at $62.48, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $87.86 indicates a potential upside of 40.6%.The mean estimate comprises seven short-term price targets with a standard deviation of $11.85. While the lowest estimate of $80 indicates a 28% increase from the current pri ...

Shares of Immunocore Holdings PLC Sponsored ADR (IMCR) have gained 20.2% over the past four weeks to close the last trading session at $36.60, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $60.47 indicates a potential upside of 65.2%.The average comprises 15 short-term price targets ranging from a low of $24 to a high of $100, with a standard deviation of $21.18. While the low ...

Shares of Nexxen International Ltd. Sponsored ADR (NEXN) have gained 16.4% over the past four weeks to close the last trading session at $11.72, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.67 indicates a potential upside of 25.2%.The mean estimate comprises nine short-term price targets with a standard deviation of $2.55. While the lowest estimate of $9 indicates a 23.2% ...

Instil Bio, Inc. (TIL) closed the last trading session at $26.75, gaining 108.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $118.67 indicates a 343.6% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $64.73. While the lowest estimate of $51 indicates a 90.7% increase from the current price level, the most optimistic analy ...

Group 1 - BioCryst Pharmaceuticals (BCRX) closed at $10.59, with a 26.2% gain over the past four weeks, and a mean price target of $16.50 indicating a 55.8% upside potential [1] - The average of 12 short-term price targets ranges from a low of $11 to a high of $30, with a standard deviation of $5.32, suggesting variability in analyst estimates [2] - Analysts show strong agreement on BCRX's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 366.9% over the past month, with six estimates revised higher and no negative revisions [12] - BCRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting stock gains, they can indicate potential price movement direction [13]